Rheonix

Rheonix

Signal active

Organization

Contact Information

Overview

Rheonix, Inc. operates as a biomedical device company. Its products include CARD (Chemistry And Reagent Device) system to miniaturize and automate new and existing assays in multiple fields. Its products and technology are used in human/veterinary in vitro diagnostics, food/water testing, SNP analysis for personalized medicine applications, homeland security/defense applications, process control and final product QC, and tissue culture analysis in a research or production setting. Rheonix, Inc. was founded in 2007 and is based in Ithaca, New York.

About

Industries

Biotechnology, Health Care, Medical Device, Homeland Security, Health Diagnostics

Founded

2007

Employees

51-100

Headquarters locations

New York, United States, North America

Social

N/A

Profile Resume

Rheonix headquartered in New York, United States, North America, operates in the Biotechnology, Health Care, Medical Device, Homeland Security, Health Diagnostics sector. The company focuses on Biotechnology and has secured $19.1B in funding across 220 round(s). With a team of 51-100 employees, Rheonix is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Rheonix, raised $12.6M. Discover more about their projects, partnerships, and impact on our platform.

Employees

N/A

Funding Rounds

Funding rounds

11

Investors

1

Lead Investors

0

Total Funding Amount

$86.7M

Details

2

Rheonix has raised a total of $86.7M in funding over 2 rounds.

Announcement dateTransaction nameNumber of InvestorsMoney raisedLead Investor
2013Early Stage Venture
2010Early Stage Venture12.6M

Investors

Rheonix is funded by 10 investors.

Investor NameLead InvestorFunding RoundPartners
Onondaga Venture Capital Fund-FUNDING ROUND - Onondaga Venture Capital Fund28.6M
Allen F. “Pete” Grum-FUNDING ROUND - Allen F. “Pete” Grum28.6M
Rheonix-FUNDING ROUND - Rheonix28.6M
Rand Capital-FUNDING ROUND - Rand Capital28.6M

Recent Activity

There is no recent news or activity for this profile.